Open AccessInterleukin-17 Alteration in First-Episode Psychosis: A Meta-Analysis
Author(s) -
Xinyu Fang,
Yi Zhang,
Weixing Fan,
Wei Tang,
Chen Zhang
Publication year - 2017
Publication title -
complex psychiatry
Language(s) - Uncategorized
Resource type - Journals
eISSN - 2673-3005
pISSN - 2673-298X
DOI - 10.1159/000481661
Subject(s) - schizophrenia (object oriented programming) , psychosis , meta analysis , pathological , drug naïve , immune system , interleukin , medicine , psychology , psychiatry , cytokine , immunology , drug
Schizophrenia is accompanied with central nervous system and peripheral immune system imbalances. Interleukin-17 (IL-17) is implicated in various immune and inflammatory processes. Aberrant levels of IL-17 have been reported in patients with schizophrenia, whereas the results are not consistent. To clarify the relationship between IL-17 and schizophrenia, we performed a meta-analysis in this study. We carried out a structured literature search in PubMed and Embase database up to April 16, 2017, and retrieved all eligible case-control studies according to the inclusion criteria. Finally, a total of 313 patients with drug-naïve first-episode psychosis and 238 healthy control subjects from 5 studies were included in our meta-analysis. There were no significant differences between first-episode psychosis patients and healthy controls with respect to the levels of IL-17 ( p = 0.21), even when we removed 2 studies which were not European samples ( p = 0.12). Our findings suggested that IL-17 may not be involved in the pathological mechanism of schizophrenia.